林扎戈利治疗子宫肌瘤患者的疼痛缓解:PRIMROSE 1和2三期试验的次要中介分析
该研究对PRIMROSE 1和2两项随机双盲安慰剂对照三期试验的汇总数据(1012例子宫肌瘤伴月经过多女性)进行事后中介分析,评估林扎戈利缓解疼痛在多大程度上由减少月经过多和缩小肌瘤体积所中介。结果显示,28%-51%的镇痛效果由月经过多减少中介,2%-8%由肌瘤体积缩小中介,残余比例44%-67%,仅在200mg无加回治疗组有统计学意义(p=0.002)。
要点
- 林扎戈利对疼痛的缓解大部分由月经过多减少中介(28%-51%,因治疗组而异)。
- 肌瘤体积缩小仅中介2%-8%的镇痛效果。
- 残余未解释效应占44%-67%,仅在200mg无加回治疗组有统计学意义(p=0.002)。
核心结论
- 在子宫肌瘤伴月经过多女性中,林扎戈利缓解疼痛的效果显著由月经过多减少(所有剂量)和肌瘤体积缩小(仅200mg)所中介。
- 需要进一步研究以识别其他中介因素。
研究设计与样本
- 对两项随机双盲安慰剂对照三期试验(PRIMROSE 1和PRIMROSE 2)汇总数据的事后中介分析。
- 研究人群为年龄≥18岁、超声确认子宫肌瘤伴月经过多的女性(n=1012)。
- 参与者随机接受林扎戈利(100mg和200mg,联合或不联合激素加回治疗)或安慰剂。
- PRIMROSE 1试验在美国94个中心开展,PRIMROSE 2试验在欧洲/美国95个中心开展。
主要发现
- 中介分析中,林扎戈利对疼痛缓解的效应有28%-51%(取决于治疗组)由其对月经过多减少的效应所解释。
- 林扎戈利对疼痛缓解的效应有2%-8%由其对肌瘤体积缩小的效应所解释。
- 残余比例范围为44%-67%(取决于治疗组),仅在林扎戈利200mg无加回治疗组有统计学意义(p=0.002)。
- 疼痛缓解定义为从基线至第24周使用数字评定量表疼痛类别变化≥2个类别(疼痛类别:无痛0,轻度1-3,中度4-6,重度7-10)。
局限性
- 需要进一步研究以识别其他中介因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Among women with uterine fibroids (UFs), we assess the extent to which the linzagolix effect on pain alleviation is explained by its effect on reducing heavy menstrual bleeding (HMB) and fibroid volume (FV). DESIGN: Post hoc analysis on the pooled data from two randomised double-blind placebo-controlled phase 3 trials. SETTING: 94 sites in the US (PRIMROSE 1 trial) and 95 sites in Europe/US (PRIMROSE 2 trial). POPULATION: Women aged ≥ 18 years with ultrasound-confirmed UFs and HMB (n = 1012). METHODS: Participants were randomised to linzagolix (100 mg and 200 mg, with and without hormonal add-back therapy) versus placebo. A post hoc mediation analysis was conducted on the pooled PRIMROSE 1 and PRIMROSE 2 data. The effect of linzagolix versus placebo on pain reduction was divided into three components (effect explained by HMB reduction associated with linzagolix, FV reduction associated with linzagolix, and remaining [not yet explained] treatment effect), with proportions of each component reported. MAIN OUTCOME MEASURES: The mediation analysis outcome was clinically significant pain reduction, defined as a change of ≥ 2 pain categories from baseline to Week 24 using the Numeric Rating Scale (pain categories: no pain (0), and mild (1-3), moderate (4-6), severe pain (7-10)). RESULTS: In the mediation analysis, 28%-51% (depending on treatment arm) of linzagolix effect on pain reduction was explained by its effect on HMB reduction, while 2%-8% was explained by its effect on FV reduction. The residual proportion ranged between 44% and 67%, depending on treatment arm, and was statistically significant only in the linzagolix 200 mg without add-back therapy arm (p = 0.002). CONCLUSIONS: This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. Further research is needed to identify additional mediating factors. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03070899 and NCT03070951.
引用
- Becker S, Dolmans MM, Herrera FC, et al. Pain Reduction in Linzagolix-Treated Patients With Uterine Fibroids: A Secondary Mediation Analysis of the PRIMROSE 1 and 2 Phase 3 Trials. BJOG. 2025. PMID: 40326221. doi:10.1111/1471-0528.18190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。